Why Kennedy Is Still — By Far — Our Best and Only HHS Secretary

My Take on Kennedy’s Evidence-Anchored Public Health Position is also My Call To Help Kennedy Succeed

The loudest criticism directed at Robert F. Kennedy Jr. since assuming leadership of the U.S. Department of Health and Human Services has come not only from long-standing institutional defenders, but also from activists who expected immediate, sweeping reversals of decades of regulatory practice in twelve months. That expectation was never structurally realistic. Federal health governance operates through statute, administrative procedure, advisory committee structures, civil service continuity, and judicial review. Reversible reform is the flick of a pen. Durable reform is procedural, not theatrical.

The record of the past year shows movement—incremental in some places, structural in others—toward a reformed public health framework grounded in consent, stratified risk analysis, and enforceable evidentiary standards. Those achievements are neither cosmetic nor symbolic. They mark a shift in how federal agencies articulate and justify policy.

Re-centering Consent and Medical Choice

One of the most visible corrections under Kennedy’s leadership has been the formal restoration of language around informed consent within federal communications. Under prior emergency conditions, public messaging often blurred the distinction between authorization and obligation. While statutory vaccine mandates for the general population were not federally imposed, federal contractor requirements and certain CMS-linked requirements created a de facto coercive climate.

Under Kennedy’s tenure, HHS has clarified that recommendations from the Centers for Disease Control and Prevention do not constitute mandates and that employment-linked medical requirements must withstand strict statutory scrutiny. Guidance issued through CMS has been revised to emphasize individualized medical exemption pathways and clearer appeal processes. This recalibration has not dismantled immunization infrastructure; it has reasserted that medical interventions are subject to informed consent principles embedded in longstanding federal ethics doctrine.

In addition, communications from HHS have increasingly distinguished between Emergency Use Authorization products and fully licensed biologics, reinforcing the regulatory distinction administered by the Food and Drug Administration. That distinction matters because it clarifies evidentiary thresholds, liability frameworks, and post-marketing surveillance obligations. Public trust depends on regulatory transparency about these differences.

This repositioning does not reject vaccination. Nothing about how HHS is structured can do that. This HHS is restoring the ethical foundation that voluntary uptake is far more stable than coerced compliance. If we are to have a viable public health in the U.S., it must be built on public confidence, not enforcement spectacle.

Precision in Population-Level Risk Reduction

The second major shift has been the increasing emphasis on stratified risk analysis rather than blanket universal framing. During the COVID era, messaging often focused on relative risk reductions without consistent public presentation of absolute risk changes by age and comorbidity status. That approach obscured meaningful heterogeneity, and it led to its own downfall.

Under Kennedy’s leadership, HHS communications have incorporated more explicit reference to age-stratified hospitalization and mortality data when discussing booster recommendations. It’s not clean enough for those who would see vaccines banned. But banning vaccines is not choice. HHS’s job, FDA in particular, is to insist and enforce that science show benefit and not goosestep to pre-determined desired results that adhere to predetermined policy. Advisory committee deliberations have increasingly highlighted absolute risk differences rather than relying solely on percentage reductions. This reflects a maturation of policy framing.

For example, booster recommendations have been contextualized around high-risk populations—elderly individuals, immunocompromised patients, and those with significant comorbidities—rather than indiscriminately framed as equally urgent across all demographics. These recalibrations align with epidemiologic reality: infection fatality rates and hospitalization risks vary dramatically by age and underlying health status. The long-term effect on morbidity and mortality in the at-risk populations will take a few years to study.

Remember that thanks to Kennedy, no one receiving the influenza vaccine is being injected with thimerosal. That alone has been a 30-year fight. I don’t see the people who have been fighting alongside Kennedy threatening to jump ship if he fails to manage to outsmart, outwit, or outmaneuver Trump tomorrow. They know that they day after Bobby does that, we lose HHS to whatever industry whore they put into the Secretary position. Because MAHA has no viable replacement candidates to continue Secretary Kennedy’s work with the diligence, the patience and the sacrifice of my friend Bobby.

Precision does not weaken the chance of a rational public health; it strengthens it. When the public sees policy aligned with differential risk and due process, credibility rises. When guidance appears one-size-fits-all despite heterogeneous data, skepticism grows.

The same logic has begun to influence broader preventive health discussions within HHS. Kennedy has emphasized metabolic health, chronic disease burden, and environmental exposures as risk multipliers that interact with infectious disease outcomes. These may seem incremental, but think back two years: If then Secretary Becerra made these moves, how would the critics within MAHA have responded? After picking their jaw off the floor, they would no doubt determine that there was some game afoot they could not quite discern. There’s an old saying about looking gift horses in the mouth. But I honestly wonder: do any of the critics fully understand the damage done to eternal grift of regulatory capture done by standards enforcement? These does not replace updated vaccination strategies, but complements them: Secretary Kennedy is responsible for all of the business of HHS, not just one’s personal priority issues. Read the room well: His moves in those areas also signal a larger risk-aware and risk-reduction ecosystem.

Why Standards Enforcement Are The Only Path

Perhaps the most consequential shift has been the rhetorical and procedural emphasis on evidentiary thresholds for product approval and recommendation.

The Food and Drug Administration operates under statutory standards requiring demonstration of safety and effectiveness. Under Kennedy’s oversight, there has been an increase from zero to regular and deep public discussion of what those standards concretely mean. Advisory committee meetings have included, for the first time it seems, the use of the word “risk” (they used to discuss “safety signals”!), more explicit dialogue about clinical endpoints versus surrogate markers, duration of protection, and post-marketing safety signal evaluation. All of this matters in ways that are immeasureably valuable because future committees under less honest brokers than Kennedy will have to lower the Kennedy bar.

These things matter because credibility depends not only on outcomes but on process transparency. When agencies clearly articulate what constitutes adequate evidence—whether prevention of severe disease, reduction in hospitalization, or mortality impact—they return the organization to the principle of neutrality.

The call for active pharmacovigilance has likewise intensified. Systems such as VAERS, VSD, and other surveillance platforms have been discussed publicly not as fringe mechanisms but as central components of safety oversight. Acknowledging adverse event monitoring as integral and acknowledging what they cannot show rather than merely adversarial strengthens the legitimacy of the entire system.

In addition, Kennedy’s tenure has emphasized the need for periodic reassessment of recommendations as new data emerge. Science is not static, and policy that reflects updated science should change. If durability of immunity wanes, if risk-benefit ratios shift due to viral evolution, or if background immunity changes, policy should adapt. That principle is not revolutionary; it is scientifically orthodox.

Institutional Sequencing Rather Than Institutional Shock

Both the critics who demand immediate dismantling of advisory bodies and those who demand overnight wholesale agency restructuring underestimate the procedural restraint that proper governance of federal departments require. The Administrative Procedure Act requires notice-and-comment rulemaking. Judicial vulnerability of rushed policy sits waiting in the coming tomorrows to undo the hard work on just, but hasty, policy shifts. Civil service protections limit personnel turnover. Congressional appropriations constrain budgetary redirection.

These are not insurmountable. But they exist.

Reform, therefore, occurs through sequencing: modifying guidance documents, adjusting advisory committee composition within statutory limits, recalibrating funding priorities at the National Institutes of Health, and altering communication frameworks before attempting structural overhaul.

Measured reform reduces the risk of judicial reversal. It also avoids destabilizing core public health infrastructure. Those who expected a year-one revolution misunderstand both law and bureaucracy.

It has not helped that the people who should have been there to help Secretary Kennedy the most have been kept out.

The Strategic Importance of Coherent Public Articulation

The next necessary step is not further internal adjustment alone; it is explicit articulation of a coherent framework that distinguishes three domains:

First, individual autonomy: no medical intervention without informed consent, clear risk disclosure, and respect for exemption pathways.

Second, population-level risk reduction: targeted recommendations based on stratified data, transparent modeling assumptions, and explicit acknowledgment of heterogeneity.

Third, enforceable approval criteria: defined clinical endpoints, transparent safety monitoring, durability assessment, and periodic review.

These domains are complementary, not contradictory. A strong and justified public health system protects vulnerable populations while respecting individual rights and maintaining transparent standards. In a system with bias and mandates sewn into the DNA of their processes and procedures, the fact that Secretary Kennedy has accomplished what he has is nothing short of miraculous.

Why the Attacks Persist

Kennedy faces criticism from two directions. Institutional defenders perceive reform rhetoric as destabilizing. Maximalist critics, who can come across as professional revolutionaries, perceive procedural pacing as betrayal. Both positions ignore the complexity of governing a department that encompasses Medicare, Medicaid, NIH research portfolios, FDA regulatory authority, and CDC epidemiologic operations.

These are not excuses. And this article is not an apologist’s letter. Far from it. From where I sit, those who refuse to see them as reasons choose to interpret them as excuses.

Structural change at that scale requires diligence and persistence. Both of those require patience. Not from the critics. From Secretary Kennedy. You don’t think he’d love to have more direct pathways? Do you think he enjoys having to entrust projects to careerists-turned-obfuscationists? I say again, because it seems to go unrecognized: Kennedy’s tenure has also required massive personal and political sacrifice. Leadership like his is rare in this day and age. And in this contorted political environment, it guarantees hostility from justly and unjustly entrenched interests on multiple sides.

Shall We Return to the Last 30 Years?

The most revealing question in the current debate is not whether reform is proceeding quickly enough. It is whether critics truly wish to return to the regulatory and public health paradigm that dominated the past three decades.

From the mid-1990s forward, federal public health governance operated under a model that increasingly centralized authority, cowed to industry, and betrayed the public trust right to their face with double-speak and coercion, all the while outsourcing evidentiary confidence to expert consensus. Advisory committees became the primary interpretive bodies. Risk–benefit calculations were often presented in aggregate terms rather than stratified detail. Relative risk reductions dominated public messaging. Surveillance systems operated, but their intentionally hobbled outputs were rarely discussed in plain language. When controversies arose, institutional reflexes tilted toward reputational defense rather than radical transparency.

During that period, the childhood vaccine schedule exploded. Liability protections under the National Vaccine Injury Compensation Program remained intact, limiting traditional tort pathways while reinforcing the expectation that regulatory rigor would substitute for market discipline. Pharmaceutical consolidation accelerated. Public-private partnerships deepened. Funding flows between federal agencies and industry intensified through cooperative agreements and research grants administered through the National Institutes of Health.

Those that impacted billions of dollars of wealth transfer hurt children the most.

None of these developments were originally inherently corrupt. Many were originally motivated by legitimate efforts to accelerate biomedical innovation and disease prevention. But over time, a Faucian architecture emerged that produced severe side effects: censorship, lockdowns, and threats to our way of life, our personal liberties. Ultimately, this led to a thunderous implosion of institutional trust. Robert F. Kennedy, Jr. was the most significant major messenger and warrior among dozens, then hundreds, then thousands, and finally millions who refused to rest until America was restored to the land of the free.

Many of those most skeptical of expert authority then gained significant platforms due to these violations, and the public learned that dissenting scientific and medical perspectives were marginalized rather than debated.

Many of those same skeptics now tend to confuse the earnest and focused enforcement of due process with delay and obfuscation.

We all recall how the COVID-19 period amplified those tensions. Emergency powers expanded rapidly. Guidance shifted frequently. Early categorical assurances about transmission prevention and durability of protection required later revision as real-world data evolved. Public health agencies such as the Centers for Disease Control and Prevention and regulatory bodies like the Food and Drug Administration kept heads spinning by updating recommendations in real time while under intense political pressure. Communication missteps that showed the truth behind the curtain compounded public doubt.

Reactionary leadership lost their footing, and they have been ousted.

To ask whether reform should proceed faster is one thing. To suggest that the pre-2020 model should be restored wholesale is another.

Shall we return to an era in which absolute risk reductions were rarely foregrounded?

Shall we return to an era in which advisory committee votes were reported without full public parsing of underlying assumptions?

Shall we return to an era in which safety surveillance discussions were largely confined to technical forums rather than presented in accessible summaries?

Shall we return to the practice of no discussion of risk before votes on vaccines?

There is a delicate political balance remaining, it must be adjusted cautiously. If we recall that a trust deficit that was actually warranted led to the downfall of the once-mighty Faucis, we might also remember that zeal for rapid reform can become easily confused in the minds of the emotionally charged with the same calls for regime change.

The problem is obvious: The alternative is regressive reform, because we will have no say in the HHS if Kennedy is ousted or leaves.

We must recall that what has been built does not abolish vaccination programs, nor does it dismantle regulatory science. It demands sharper evidentiary articulation. It raises the bar by acknowledging there is one. It requires that population-level benefit claims be matched with transparent denominators. It insists that adverse event monitoring be treated as essential rather than adversarial. It places informed consent at the center of policy rather than as an afterthought to compliance.

The last thirty years produced a massive chasm - a widening cultural distance - between agencies and the public they serve.

Throwing HHS back to the wolves is returning to that equilibrium, not stability. It would be woefully regressive.

The present moment calls for clamor for more in the form of Kennedy’s recalibrated framework—one that retains scientific rigor while correcting structural blind spots. If reform pauses now out of impatience or fatigue, the opportunity for durable service and impact will narrow.

The choice is not between revolution and restoration. It is between continual improvement and regression.

History will judge whether the system had the courage to evolve—or whether it sought refuge in familiar patterns that already fractured public confidence via confusion of endurance with expediency.

A Final Reality Check

A year is insufficient to overturn decades of rancid regulatory culture. It is sufficient, however, to set direction. To those who see this as an apologist’ message, you have completely missed the point. But I thank you for making it this far.

Under Kennedy’s leadership, HHS has moved mountains: re-centering consent, refining and implementing risk stratification, and clarifying evidentiary standards. These are foundational shifts, not window-dressing. They strengthen, rather than weaken, public health credibility.

We fought together for the right to stand up and criticize false leadership. We won. We fought together for the right to disagree - and to state that we disagree. We won. It was not cheap. Some of us have sacrificed nearly everything - including family relationships - to steward public health back into the sanity lane so humanity has a future free from medical slavery.

Will we win?

Rational criticism plays an important role in helping us find the guardrails, and in finding effective pathways forward. Ask yourself: “Have I offered to help Secretary Kennedy achieve his goals in the ways that he knows he must operate? Have I done all I can do establish programs to do things he cannot?”

Shall we allow HHS to slide all of medicine and science on medicine back into lockstep?

The measure of success is not whether every critic is satisfied. The measure of success is whether every department’s operating philosophy aligns with ethical autonomy, epidemiologic precision, and regulatory transparency.

On those axes, the trajectory is clear.

And that is why Secretary Kennedy remains, by far, the strongest steward the department has had in decades. If not ever in the history of the institution.

Postscript:

Lori Martin Gregory released a new podcast episode yesterday wherein she asks really, really tough questions.

It will be tough for many to view. It was tough for me to view.

I wholeheartedly encourage you to view the podcast and to view the questions that she asks at the end as something a bit more than rhetorical. They challenge the notion that we can see everything from where we sit. I don’t see everything from where I sit, but I see a lot. And I have to say that her questions have answers - and it is up to us, the vaccine risk aware, the health freedom movement, and MAHA to make sure that shifts in power occur in ways that makes Kennedy’s shot at success in revolutionary reform of public health inevitable. His is our shared task.

At the same time, a mature movement will embrace the feedback it receives, learn from it, and acknowledge the pain experienced by those fighting to prevent harms they have endured.

Robert F. Kennedy, Jr. has never once shied away from that pain. The pain of loss drives him.

My call to rally to help Kennedy succeed is not out of loyalty, it not pandering. In my experience, he never demands or expects it. He actually prefers a well-timed challenge. Yet another yes-man around Kennedy underestimates how much he values rational discourse.

My call to rally to help Kennedy succeed is something far, far more important.

It is self-respect. Mine. And yours.